Literature DB >> 11358415

How does one assess early rheumatoid arthritis in daily clinical practice?

P L van Riel1, H R Schumacher.   

Abstract

In past years, consensus has been reached on the assessment of rheumatoid arthritis in clinical trials. Next to a core set of disease activity variables, response criteria have been developed and validated. These criteria are, however, of limited value in daily clinical practice. In this situation, emphasis should be paid to accurate measurement of disease activity on a continuous scale using the lowest possible number of core set variables. Different studies have shown that the DAS28 is a valuable instrument for this purpose. Many factors have been identified to possess a prognostic value; however, the IgM rheumatoid factor is still the only one which is of any importance in daily clinical practice. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358415     DOI: 10.1053/berh.2000.0126

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  20 in total

1.  Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis.

Authors:  Alvin Yee; Tyler Webb; Andrea Seaman; Maria Infantino; Francesca Meacci; Mariangela Manfredi; Maurizio Benucci; Gabriella Lakos; Ennio Favalli; Tommaso Schioppo; Tommaso Shioppo; Pier-Luigi Meroni; Michael Mahler
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: a randomized controlled clinical trial.

Authors:  Sarah Brien; Laurie Lachance; Phil Prescott; Clare McDermott; George Lewith
Journal:  Rheumatology (Oxford)       Date:  2010-11-13       Impact factor: 7.580

3.  Inter- and intra-observer agreement of high-resolution ultrasonography and power Doppler in assessment of joint inflammation and bone erosions in patients with rheumatoid arthritis.

Authors:  Mario Alfredo Chávez-López; Cristina Hernández-Díaz; Carlos Moya; Carlos Pineda; Lucio Ventura-Ríos; Ingrid Möller; Esperanza Naredo; Rolando Espinosa; Angélica Peña; Alejandro Rosas-Cabral; Emilio Filippucci
Journal:  Rheumatol Int       Date:  2012-01-25       Impact factor: 2.631

4.  Negative and positive illness representations of rheumatoid arthritis: a latent profile analysis.

Authors:  Sam Norton; Lyndsay D Hughes; Joseph Chilcot; Amanda Sacker; Sandra van Os; Adam Young; John Done
Journal:  J Behav Med       Date:  2013-03-30

5.  The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis.

Authors:  Ratanapha Phuan-Udom; Nittaya Lektrakul; Wanruchada Katchamart
Journal:  Clin Rheumatol       Date:  2018-07-23       Impact factor: 2.980

6.  Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin.

Authors:  Patrick A M Jansen; Diana Rodijk-Olthuis; Edward J Hollox; Marijke Kamsteeg; Geuranne S Tjabringa; Gys J de Jongh; Ivonne M J J van Vlijmen-Willems; Judith G M Bergboer; Michelle M van Rossum; Elke M G J de Jong; Martin den Heijer; Andrea W M Evers; Mieke Bergers; John A L Armour; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

7.  Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis.

Authors:  Young Ho Lee; Sang-Cheol Bae; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2014-04-12       Impact factor: 2.631

8.  Influence of guideline adherence on outcome in a randomised controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritis.

Authors:  J Fransen; R F J M Laan; M A F J Van Der Laar; T W J Huizinga; P L C M Van Riel
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

9.  Factors predicting the outcome of customised foot orthoses in patients with rheumatoid arthritis: a prospective cohort study.

Authors:  Marike van der Leeden; Karin Fiedler; Annelies Jonkman; Rutger Dahmen; Leo D Roorda; Dirkjan van Schaardenburg; Joost Dekker
Journal:  J Foot Ankle Res       Date:  2011-02-10       Impact factor: 2.303

10.  Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort.

Authors:  Daniel F McWilliams; Patrick D W Kiely; Adam Young; David A Walsh
Journal:  BMC Musculoskelet Disord       Date:  2013-05-01       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.